心不全における至適療法の実施のための協同プログラムの根拠とデザイン
Alexander J Blood1,2,3, Ozan Unlu1,2,3,4, John W Ostrominski1,2,3,5
1Accelerator for Clinical Transformation, Brigham and Women's Hospital, Boston, Massachusetts, USA.
Clinical cardiology
|February 7, 2026
まとめ
COPILOT-HF研究は、心不全(HF)患者のガイドライン指向型医薬品療法(GDMT)を改善するための、遠隔ナビゲーター主導戦略をテストしました。このアプローチは、GDMTの採用が遅いという問題に対処し、全駆出率にわたるHF治療の最適化を目的としています。
科学分野:
- 循環器病学
- 薬理学
- 医療サービス研究
背景:
- ガイドライン指向型医薬品療法(GDMT)は、心不全(HF)患者に significant clinical benefits を提供しますが、その採用は依然として最適ではありません。
- GDMT実施を改善するための既存の戦略は、しばしば非効果的、リソース集約的、またはHFと駆出率低下(HFrEF)に限定されています。
- HF(HFpEFを含む)全般にわたるGDMTを最適化するための、スケーラブルで包括的なアプローチが critical need です。
研究 の 目的:
- COPILOT-HF(Cooperative Program for ImpLementation of Optimal Therapy in Heart Failure)スタディの有効性を評価すること。
- 遠隔ナビゲーター主導のGDMT最適化戦略と、標準的な患者および提供者教育との比較。
- 心不全駆出率全般にわたるGDMT最適化の評価。
主な方法:
- 実用的、ランダム化、オープンラベル介入試験デザイン。
- GDMT最適化のための包括的、遠隔、ナビゲーター主導、アルゴリズム駆動戦略の実施。
- GDMTに関する患者および提供者教育に焦点を当てた対照介入との比較。
主要な成果:
- 主要有効性エンドポイントは、3か月時点での最適HF治療を受けている患者の割合です。
- 二次転帰には、6か月および12か月時点での最適HF治療率が含まれます。
- 入院および死亡率を含む医療資源の利用も評価されます。
結論:
- COPILOT-HF研究は、遠隔薬剤師主導の薬物滴定戦略の有効性を決定します。
- この戦略は、心不全全般にわたるGDMT実施の改善を目的としています。
- この結果は、HF薬物療法の最適化のためのスケーラブルなソリューションに情報を提供します。
関連する概念動画
Heart Failure VI: Adjunct Therapies
368
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
368
Heart Failure II: Pathophysiology
975
Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
975
Pathophysiology of Heart Failure
3.8K
Heart failure (HF) is a progressive syndrome involving ventricles that leads to inadequate cardiac output. It can be classified based on location and output or ejection fraction. Ejection fraction (EF) is an essential measurement in the diagnosis and surveillance of HF. Reduced EF corresponds to systolic heart failure (HFrEF). However, HF with preserved ejection fraction (HFpEF) is becoming increasingly prevalent. Also known as diastolic HF, this form of HF is related to aging. The...
3.8K
Heart Failure I: Introduction
924
Heart failure refers to a clinical syndrome caused by structural or functional cardiac disorders that prevent the heart from pumping an adequate amount of blood to meet the body's metabolic needs. This condition often arises from myocardial infarction or ischemia, leading to decreased cardiac output, reduced tissue perfusion, impaired gas exchange, fluid volume imbalance, and decreased functional ability.Heart failure can result from disruptions in the mechanisms that regulate cardiac output...
924
Cooperative Allosteric Transitions
8.8K
Cooperative allosteric transitions can occur in multimeric proteins, where each subunit of the protein has its own ligand-binding site. When a ligand binds to any of these subunits, it triggers a conformational change that affects the binding sites in the other subunits; this can change the affinity of the other sites for their respective ligands. The ability of the protein to change the shape of its binding site is attributed to the presence of a mix of flexible and stable segments in the...
8.8K
Cooperative Binding of Transcription Regulators
7.4K
Transcriptional regulators bind to specific cis-regulatory sequences in the DNA to regulate gene transcription. These cis-regulatory sequences are very short, usually less than ten nucleotide pairs in length. The short length means that there is a high probability of the exact same sequence randomly occurring throughout the genome. Since regulators can also bind to groups of similar sequences, this further increases the chances of random binding. Transcriptional regulators form...
7.4K


